China · Delayed Price · Currency is CNY Sansure Biotech Statistics
Total Valuation
Sansure Biotech has a market cap or net worth of CNY 9.14 billion. The enterprise value is 6.92 billion.
| Market Cap | 9.14B |
| Enterprise Value | 6.92B |
Important Dates
The last earnings date was Thursday, August 27, 2026.
| Earnings Date | Aug 27, 2026 |
| Ex-Dividend Date | Jun 22, 2026 |
Share Statistics
Sansure Biotech has 574.86 million shares outstanding. The number of shares has decreased by -0.67% in one year.
| Current Share Class | 574.86M |
| Shares Outstanding | 574.86M |
| Shares Change (YoY) | -0.67% |
| Shares Change (QoQ) | -14.53% |
| Owned by Insiders (%) | 38.96% |
| Owned by Institutions (%) | 11.32% |
| Float | 298.89M |
Valuation Ratios
The trailing PE ratio is 69.04 and the forward PE ratio is 36.41.
| PE Ratio | 69.04 |
| Forward PE | 36.41 |
| PS Ratio | 5.69 |
| PB Ratio | 1.29 |
| P/TBV Ratio | 1.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 29.38 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 51.59 |
| EV / Sales | 4.31 |
| EV / EBITDA | 24.34 |
| EV / EBIT | 136.72 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.67, with a Debt / Equity ratio of 0.22.
| Current Ratio | 4.67 |
| Quick Ratio | 4.18 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | 5.36 |
| Debt / FCF | -26.05 |
| Interest Coverage | 2.17 |
Financial Efficiency
Return on equity (ROE) is 1.28% and return on invested capital (ROIC) is 1.01%.
| Return on Equity (ROE) | 1.28% |
| Return on Assets (ROA) | 0.33% |
| Return on Invested Capital (ROIC) | 1.01% |
| Return on Capital Employed (ROCE) | 0.59% |
| Weighted Average Cost of Capital (WACC) | 6.16% |
| Revenue Per Employee | 755,278 |
| Profits Per Employee | 63,080 |
| Employee Count | 2,128 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 0.99 |
Taxes
In the past 12 months, Sansure Biotech has paid 7.87 million in taxes.
| Income Tax | 7.87M |
| Effective Tax Rate | 7.85% |
Stock Price Statistics
The stock price has decreased by -21.64% in the last 52 weeks. The beta is 0.49, so Sansure Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | -21.64% |
| 50-Day Moving Average | 15.57 |
| 200-Day Moving Average | 17.54 |
| Relative Strength Index (RSI) | 53.27 |
| Average Volume (20 Days) | 7,671,255 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sansure Biotech had revenue of CNY 1.61 billion and earned 134.24 million in profits. Earnings per share was 0.23.
| Revenue | 1.61B |
| Gross Profit | 1.18B |
| Operating Income | 50.65M |
| Pretax Income | 100.37M |
| Net Income | 134.24M |
| EBITDA | 276.71M |
| EBIT | 50.65M |
| Earnings Per Share (EPS) | 0.23 |
Balance Sheet
The company has 3.82 billion in cash and 1.53 billion in debt, with a net cash position of 2.30 billion or 3.99 per share.
| Cash & Cash Equivalents | 3.82B |
| Total Debt | 1.53B |
| Net Cash | 2.30B |
| Net Cash Per Share | 3.99 |
| Equity (Book Value) | 7.07B |
| Book Value Per Share | 13.16 |
| Working Capital | 3.98B |
Cash Flow
In the last 12 months, operating cash flow was 311.15 million and capital expenditures -369.68 million, giving a free cash flow of -58.53 million.
| Operating Cash Flow | 311.15M |
| Capital Expenditures | -369.68M |
| Depreciation & Amortization | 226.06M |
| Net Borrowing | 551.51M |
| Free Cash Flow | -58.53M |
| FCF Per Share | -0.10 |
Margins
Gross margin is 73.41%, with operating and profit margins of 3.15% and 8.35%.
| Gross Margin | 73.41% |
| Operating Margin | 3.15% |
| Pretax Margin | 6.24% |
| Profit Margin | 8.35% |
| EBITDA Margin | 17.22% |
| EBIT Margin | 3.15% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.52, which amounts to a dividend yield of 3.31%.
| Dividend Per Share | 0.52 |
| Dividend Yield | 3.31% |
| Dividend Growth (YoY) | -0.38% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 245.06% |
| Buyback Yield | 0.67% |
| Shareholder Yield | 3.98% |
| Earnings Yield | 1.47% |
| FCF Yield | -0.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 1, 2022. It was a forward split with a ratio of 1.48.
| Last Split Date | Jun 1, 2022 |
| Split Type | Forward |
| Split Ratio | 1.48 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |